Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Share News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
64.60    0.90 (1.41%)
Bid:
64.10
Ask:
64.60
Spread: 0.50 (0.78%)
Market Cap: £570.69m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

IP Group posts narrower first-half loss

Wed, 17th Sep 2025 08:47

(Sharecast News) - IP Group reported a narrower first-half loss on Tuesday as it hailed progress across its portfolio, including a landmark US flotation, while reiterating its confidence in delivering over £250m of exits by 2027.

The FTSE 250 deeptech investor posted a net loss of £43m for the six months ended 30 June, down from £109.9m a year earlier, as net asset value per share edged 1.5% lower to 96.2p.

NAV stood at £883.1m, down from £1.07bn at the same point in 2024, though the group said that had since recovered to around 100p per share as of 12 September on the back of gains in its listed holdings.

Portfolio company Hinge Health floated on the New York Stock Exchange at $32 a share and ended the period at $52, valuing IP Group's remaining stake at £39.1m, while Oxford Nanopore beat guidance with £105.6m of first-half revenue and lower losses.

The group also highlighted a series of funding rounds across its holdings, including $15m at Accelercomm, $10m at Lumai, €30m at Tado, €14.2m at Vytal and £12m at Mixergy, with total portfolio fundraising reaching £372m in the half.

Cash proceeds from exits rose ninefold year-on-year to £30.3m, supported by a £25m share buyback completed during the period, with a further £20m extension launched.

IP Group invested £36m across 21 companies and ended the half with gross cash of £237.3m, up from £161.3m a year earlier.

It said fair value gains in its quoted holdings had added £32m since 30 June, including a £23m increase in Oxford Nanopore.

"The group made strong progress in the first half of the year, delivering over £30m in cash proceeds, a near ninefold increase year-on-year," said chief executive Greg Smith.

"The successful IPO of Hinge Health on the NYSE was a standout milestone, and together with gains in Oxford Nanopore, underscores the resilience and quality of our portfolio.

"With NAV per share now at 100p as of 12 September, a strong pipeline of new and maturing companies and improving market sentiment, the group remains confident of delivering more than £250m of exits from private company holdings by the end of 2027.

"As one of the world's most experienced university IP investors, IP Group is uniquely positioned to capitalise on fiscal reform and rising demand for high-growth innovation while remaining firmly focused on delivering long-term value for our shareholders."

At 0824 BST, shares in IP Group were up 0.54% at 55.8p.

Reporting by Josh White for Sharecast.com.

Related News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

Ip Group News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

LONDON BROKER RATINGS: Jefferies cuts National Grid to 'hold'
18 Mar 2026

LONDON BROKER RATINGS: Jefferies cuts National Grid to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

IP Group asset value grows, remains confident in biotech potential
17 Mar 2026

IP Group asset value grows, remains confident in biotech potential

(Alliance News) - IP Group PLC on Tuesday highlighted a successful acquisition by portfolio holding Pfizer Inc, as the investor in science and technol...

LONDON MARKET OPEN: FTSE 100 outperforms Europe as oil rises
17 Mar 2026

LONDON MARKET OPEN: FTSE 100 outperforms Europe as oil rises

(Alliance News) - Stock prices in London opened mixed on Tuesday, as the FTSE 100 was helped by oil majors to outperform European peers, while Trustpi...

IP Group commits USD35 million to autonomous driving firm Oxa
4 Mar 2026

IP Group commits USD35 million to autonomous driving firm Oxa

(Alliance News) - Shares in IP Group PLC rose on Wednesday, as the firm noted its participation in a USD103 million fundraise by Oxa Autonomy Ltd.

Oxa secures $103m in Series D funding
4 Mar 2026

Oxa secures $103m in Series D funding

(Sharecast News) - Intellectual property investor IP Group revealed on Wednesday that portfolio company Oxa Autonomy has completed its Series D fundin...